Previous 10 | Next 10 |
2seventy bio Inc. (TSVT) is expected to report $-1.31 for Q3 2023
2023-10-26 17:17:24 ET More on 2seventy bio bluebird bio And 2seventy bio - Spinner And Spun: The Better Bet In Cell Therapy 2seventy bio, Inc. 2023 Q2 - Results - Earnings Call Presentation 2seventy bio, Inc. (TSVT) Q2 2023 Earnings Call Transcript 2seventy ...
2023-10-26 12:53:31 ET Gainers: MSP Recovery ( LIFW ) +31% . Blueprint Medicines Corp ( BPMC ) +27% . Global Mofy Metaverse Ltd ( GMM ) +23% . Endeavor Group Holdings ( EDR ) +23% . Impinj ( PI ) +22% . Bel Fuse ( BELFB )...
2023-10-26 09:56:33 ET More on Health Care Select Sector SPDR Health Care Select Sector Fund ETF: Riding The Healthcare Boom Stocks to watch in the Health Care sector as earnings close in BofA reports 10th consecutive week of equity inflows For further detail...
2023-10-26 08:35:12 ET More on Golden Minerals, Opendoor Technologies, etc. Opendoor Technologies Inc. (OPEN) Goldman Sachs 2023 Communacopia & Technology Conference Transcript Opendoor: The Bottom May Be Here For The Brave Rentokil Initial: Thriving Compounder I...
2023-10-26 07:45:00 ET More on Bristol-Myers Bristol-Myers Squibb Acquisition Of Mirati Makes Sense Bristol-Myers Squibb: Time To Get Greedy Bristol-Myers' Mirati Takeover: Pharma Is Either Buying Crown Jewels Or A Dud Bristol-Myers Squibb Company Non-GAAP EP...
2023-09-17 08:35:00 ET Summary Shanghai Hasten Biopharma has entered a $325 million agreement for greater China rights to a PCSK9 inhibitor from LIB Therapeutics. Insilico Medicine has out-licensed global rights to a small molecule inhibitor to Exelixis for BRCA-mutated tumors. ...
2023-09-15 18:46:28 ET Summary Bluebird bio and 2seventy bio are struggling as small biotechs in the challenging field of cell therapies. Bluebird has a longer history as a public company and has established itself as a gene therapy leader with FDA-approved therapies. Both com...
2023-09-13 10:00:09 ET More on Health Care Select Sector SPDR Seeking Alpha’s Quant Rating on Health Care Select Sector SPDR Dividend scorecard for Health Care Select Sector SPDR Stagflation Playbook: Short Tech (QQQ/ARKK) And Long Healthcare ( XLV ) ...
2023-09-12 07:59:29 ET More on 2seventy bio Seeking Alpha’s Quant Rating on 2seventy bio Historical earnings data for 2seventy bio Financial information for 2seventy bio 2seventy bio: Nothing Properly Explains The Low Valuation 2seventy bio dow...
News, Short Squeeze, Breakout and More Instantly...
- Divestiture Supports Company Focus on Development and Commercialization of Abecma - 2seventy bio, Inc . (Nasdaq: TSVT), announced today the completion of an asset purchase agreement (“APA”) by Novo Nordisk. Under the terms of the APA, Novo Nordisk has acquired th...
2024-06-06 06:15:03 ET Goldman Sachs analyst issues SELL recommendation for TSVT on June 6, 2024 05:06AM ET. The previous analyst recommendation was Buy. TSVT was trading at $4.56 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current an...
2seventy bio, Inc . (Nasdaq: TSVT) will announce its first quarter 2024 financial results on Wednesday, May 8, 2024. A conference call and webcast will be held at 8:00 a.m. ET. Participants can access the conference call live via webcast which will be available on the Investors and Media pa...